Neoadjuvant endocrine treatment and clinical outcome in ER positive breast cancer – a single UK cancer centre experience
Background: Neoadjuvant endocrine treatment (NET) is increasingly used in early stage ER positive breast cancer (EBC) mainly in post-menopausal patients. This approach shows response rates (RR) comparable to neoadjuvant chemotherapy for some patients but randomised trials are limited. We set out to review the RR in patients treated with NET at our UK centre.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: S. Benafif, K. Rapti, C. Nattress, M. Akay, R. Roylance, F. Raja, E. Spurrell, A. Konstantis, E. Papadimitraki Tags: POSTERS B: Systemic Treatment Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Men | Menopause | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy